Herpes zoster
☆ I le 2022 Stiftung Warentest i'uga mai Siamani, o le fa'amalieina o tagata fa'atau i ModelDerm sa na'o sina maualalo ifo nai lo fa'atalanoaga telemedicine totogi.
Herpes zoster papa'u ile ua ma le tauau
References
Shingles, e mafua mai i le toe fa'afouina o le virus varicella zoster e mafua ai le tanesusu, e aafia ai le tusa ma le 1 miliona tagata i tausaga taʻitasi i le Iunaite Setete, ma le lamatiaga o le olaga atoa e 30%. O i latou e fa'avaivaia le puipuiga o le tino e matua'i fa'atupula'ia i le atia'e o shingles, ma fa'ailoga e masani ona amata i le malaise, tiga o le ulu, ma le fiva vaivai, sosoo ai ma lagona e le masani ai o le pa'u i ni nai aso a'o le'i aliali mai se mageso. O lenei mageso, e masani ona aliali mai i se vaega patino o le tino, e faasolosolo atu mai le ma'i ma'i ma'i e oo atu i papala e sili atu i le vaiaso i le sefulu aso. O togafitiga fa'anatinati i vaila'au fa'ama'i (acyclovir, valacyclovir, or famciclovir) i totonu ole 72 itula ole oso fa'amata'u e taua tele. Postherpetic neuralgia, o se faʻalavelave masani e faʻaalia i le umi o le tiga i le vaega o loʻo aʻafia, e aʻafia ai pe tusa ma le tasi i le lima tagata maʻi ma e manaʻomia le faʻaauau pea o le puleaina ma vailaʻau e pei o le gabapentin, pregabalin, poʻo nisi vailaʻau faʻamaʻi, faʻatasi ai ma vailaʻau e pei o le lidocaine poʻo le capsaicin. Ole tui ole varicella zoster e fautuaina mo tagata matutua e 50 tausaga ma luga atu e fa'aitiitia ai le lamatiaga ole ma'i.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Shingles, caused by the reactivation of the varicella zoster virus responsible for chickenpox, affects around 1 million people annually in the United States, with a lifetime risk of 30%. Those with weakened immune systems are significantly more prone to developing shingles, with symptoms typically starting with malaise, headache, and a mild fever, followed by unusual skin sensations a few days before the appearance of a rash. This rash, usually appearing in a specific area of the body, progresses from clear blisters to crusted sores over a week to ten days. Prompt treatment with antiviral medications (acyclovir, valacyclovir, or famciclovir) within 72 hours of rash onset is crucial. Postherpetic neuralgia, a common complication characterized by prolonged pain in the affected area, affects about one in five patients and requires ongoing management with medications such as gabapentin, pregabalin, or certain antidepressants, along with topical agents like lidocaine or capsaicin. Vaccination against the varicella zoster virus is recommended for adults aged 50 and above to reduce the risk of shingles.
Herpes zoster e masani ona tupu soo i tagata ua ta'i 50 tausaga ma matutua atu, oi latou e vaivai le puipuiga o le tino, ma i latou o lo'o inuina vaila'au fa'agata. E afua mai i le toe fa'afouina ole virus varicella-zoster, ole siama lava lea e mafua ai le tanesusu. O auga e pei o le fiva, tiga, ma le mageso e masani lava ona muamua atu i le aliali mai o le mageso. O le fa'alavelave sili ona taatele o le post-herpetic neuralgia, o le tiga faifai pea o neura pe a uma le mageso. O fa'alavelave fa'alavelave ma fa'alavelave e feso'ota'i ma le herpes zoster e eseese e fa'atatau i le matua, soifua maloloina fa'aletonu, ma le taimi e amata ai togafitiga. O tui mo tagata ta'ito'atasi e 60 tausaga ma luga atu ua fa'aalia e matua fa'aitiitia ai le tupu mai o le herpes zoster ma le post-herpetic neuralgia. O le amataina o vaila'au fa'ama'i ma fa'ama'i tiga i totonu ole 72 itula talu ona amata mageso e mafai ona fa'aitiitia ai le ogaoga ma fa'alavelave ole herpes zoster ma le neuralgia post-herpetic.
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
Herpes zoster tends to occur more frequently in people aged 50 and older, those with weakened immune systems, and those taking immunosuppressant medications. It's triggered by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. Symptoms like fever, pain, and itching commonly precede the appearance of the characteristic rash. The most common complication is post-herpetic neuralgia, which is persistent nerve pain after the rash clears up. The risk factors and complications associated with herpes zoster vary depending on age, immune health, and timing of treatment initiation. Vaccination for individuals aged 60 and above has been shown to significantly reduce the occurrence of herpes zoster and post-herpetic neuralgia. Starting antiviral medications and pain relievers within 72 hours of rash onset can lessen the severity and complications of herpes zoster and post-herpetic neuralgia.
O fa'ata'ita'iga a le falema'i a'o le'i fa'atagaina, o lo'o fa'ailoa mai ai e 50 i le 70% le tui o le zoster ola, ae sili atu le lelei o le tui fa'aopoopo, e amata mai i le 90 i le 97%. I suʻesuʻega moni o le lalolagi, latou te lagolagoina faʻamatalaga o faʻataʻitaʻiga, e faʻaalia ai o le tui ola e tusa ma le 46% aoga, ae o le recombinant e tusa ma le 85%.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
The pre-licensure clinical trials show the efficacy of the live zoster vaccine to be between 50 and 70% and for the recombinant vaccine to be higher at 90 to 97%. Real-world effectiveness studies, with a follow-up of approximately 10 years, were reviewed in this article. These data corroborated the efficacy studies, with vaccine effectiveness being 46% and 85% for the live and recombinant vaccines, respectively.
O le tanesusu, e ta'ua fo'i o le varicella, e mafua mai i le fa'ama'i muamua i le siama, e masani ona tupu a'o laiti po'o le talavou. O le taimi lava e malolo ai le tanesusu, e mafai ona tumau le siama (moe) i sela neura o le tagata mo le tele o tausaga poʻo le sefulu tausaga, mulimuli ane e mafai ona toe faʻagaoioia. Herpes zoster e maua pe a toe fa'agaoioia le virusi varicella moe. Ona fealua'i lea o le siama i tino neura e oo atu i i'uga o neura i le pa'u, ma maua ai le ma'i. I le taimi o le fa'ama'i o le herpes zoster , o le a'afia i le virusi varicella o lo'o maua i le herpes zoster ma'i pa'u e mafai ona mafua ai le tanesusu i se tasi e le'i maua i le tanesusu.
O a'afiaga mo le toe fa'afouina o le siama moe e aofia ai le matua, le lelei o le puipuiga, ma le maua i le tanesusu a'o le'i atoa le 18 masina. O le virusi Varicella zoster e le tutusa ma le herpes simplex virus, e ui lava e tutusa uma i le aiga o herpesviruses.
Herpes zoster tui e fa'aitiitia ai le lamatiaga o le herpes zoster i le 50% i le 90%. E fa'aitiitia ai fo'i fua faatatau o neuralgia postherpetic, ma, pe a tupu herpes zoster , lona ogaoga. Afai e tupu le herpes zoster , o vaila'au fa'ama'i e pei o le aciclovir e mafai ona fa'aitiitia ai le ogaoga ma le umi o fa'ama'i pe a amata i totonu ole 72 itula talu ona aliali mai le mageso.
○ Togafiti
Afai o lo'o sosolo vave le ma'i, va'ai lau foma'i i se taimi vave e mafai ai mo togafitiga fa'ama'i.
E manaʻomia uma vailaʻau faʻamaʻi ma vailaʻau neuralgia. E tatau ona e malolo ma taofi le inu ava malosi.
#Acyclovir
#Fancyclovir
#Valacyclovir
#Gabapentin
#Pregabalin